Index -
P/E -
EPS (ttm) -0.34
Insider Own 13.79%
Shs Outstand 96.27M
Perf Week -1.77%
Market Cap 24.69B
Forward P/E 25.59
EPS next Y 2.64
Insider Trans -0.01%
Shs Float 82.99M
Perf Month 15.75%
Income 17.60M
PEG -
EPS next Q 0.45
Inst Own 78.11%
Short Float 5.56%
Perf Quarter 50.13%
Sales 2.71B
P/S 9.12
EPS this Y 25.11%
Inst Trans 1.47%
Short Ratio 5.11
Perf Half Y 55.12%
Book/sh 6.95
P/B 9.74
EPS next Y 34.65%
ROA 0.20%
Short Interest 4.62M
Perf Year 144.86%
Cash/sh 3.11
P/C 21.77
EPS next 5Y 32.16%
ROE 2.83%
52W Range 27.40 - 69.86
Perf YTD 56.78%
Dividend Est. 1.68 (2.48%)
P/FCF 399.28
EPS past 5Y -
ROI 0.91%
52W High -3.12%
Beta 1.52
Dividend TTM 1.75 (2.59%)
Quick Ratio -
Sales past 5Y 29.25%
Gross Margin 96.45%
52W Low 147.01%
ATR (14) 1.72
Dividend Ex-Date Aug 16, 2024
Current Ratio -
EPS Y/Y TTM -80.99%
Oper. Margin -0.76%
RSI (14) 70.55
Volatility 2.51% 2.76%
Employees 1850
Debt/Eq 1.72
Sales Y/Y TTM 21.75%
Profit Margin 0.65%
Recom 2.07
Target Price 62.86
Option/Short Yes / Yes
LT Debt/Eq 1.72
EPS Q/Q -1327.15%
Payout -
Rel Volume 1.31
Prev Close 68.39
Sales Surprise -0.53%
EPS Surprise 14.92%
Sales Q/Q 23.04%
Earnings Nov 04 BMO
Avg Volume 904.00K
Price 67.68
SMA20 5.36%
SMA50 16.32%
SMA200 42.70%
Trades
Volume 1,183,932
Change -1.04%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-12-24 Initiated
Wells Fargo
Overweight
$60
May-10-24 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$43 → $52
Jan-04-24 Initiated
TD Cowen
Market Perform
$38
Dec-06-23 Resumed
BMO Capital Markets
Market Perform
$36
Nov-30-23 Resumed
Goldman
Buy
$43
May-19-23 Initiated
Citigroup
Buy
$32
Jan-24-23 Downgrade
JP Morgan
Overweight → Neutral
$35 → $34
Oct-19-22 Initiated
Credit Suisse
Neutral
$27.50
Oct-17-22 Initiated
Jefferies
Hold
$30
Oct-14-22 Downgrade
Exane BNP Paribas
Outperform → Neutral
$32
Jun-08-22 Initiated
JMP Securities
Mkt Perform
Show Previous Ratings
Oct-29-24 03:38PM
Oct-24-24 12:00AM
Oct-21-24 03:00PM
Oct-14-24 11:38AM
Oct-07-24 08:00AM
04:22PM
Loading…
Sep-30-24 04:22PM
04:01PM
(Investor's Business Daily)
09:30AM
08:44AM
07:53AM
07:46AM
07:00AM
06:55AM
(Associated Press Finance)
06:13AM
Sep-27-24 01:44PM
10:00AM
Loading…
10:00AM
07:00AM
(The Wall Street Journal)
Sep-26-24 05:00PM
Sep-16-24 09:05PM
Sep-11-24 07:55AM
Sep-06-24 03:08PM
Sep-03-24 04:20PM
04:05PM
Aug-23-24 05:46AM
Aug-22-24 09:00AM
Aug-15-24 01:00AM
Aug-06-24 03:39PM
(The Wall Street Journal)
08:00AM
Jul-18-24 12:06AM
Jul-16-24 04:49AM
08:00AM
Loading…
Jul-10-24 08:00AM
Jul-04-24 12:00PM
Jun-28-24 08:00AM
07:55AM
Jun-17-24 09:30AM
Jun-08-24 05:30PM
May-29-24 08:00AM
May-22-24 08:07AM
May-08-24 12:54PM
09:25AM
08:00AM
May-02-24 01:00PM
May-01-24 10:01AM
Apr-24-24 12:10PM
Apr-17-24 09:00AM
Apr-15-24 09:02AM
(The Wall Street Journal)
Apr-04-24 08:00AM
Apr-03-24 08:00AM
Mar-29-24 01:13AM
Mar-24-24 11:00AM
Mar-07-24 10:05AM
(The Wall Street Journal)
Mar-04-24 09:40AM
Mar-01-24 11:36PM
Feb-29-24 05:25PM
09:19AM
Feb-28-24 09:10PM
Feb-27-24 08:50AM
Feb-26-24 09:11AM
06:25AM
Feb-21-24 09:06AM
Feb-20-24 01:46PM
Feb-19-24 01:16PM
Feb-14-24 08:00AM
Feb-13-24 09:25AM
08:00AM
Feb-06-24 10:00AM
Feb-05-24 10:27AM
Jan-24-24 06:32PM
Jan-23-24 04:58PM
08:47AM
08:00AM
Jan-18-24 05:46PM
Jan-16-24 03:48PM
(The Wall Street Journal)
09:00AM
Jan-11-24 08:00AM
Jan-10-24 08:00AM
Dec-27-23 07:47AM
Dec-18-23 01:24PM
Dec-15-23 07:55AM
Dec-01-23 06:06AM
Nov-21-23 08:00AM
Nov-07-23 03:20PM
(The Wall Street Journal)
08:00AM
05:30AM
(The Wall Street Journal)
Nov-06-23 08:33AM
Nov-02-23 07:00AM
Oct-11-23 08:00AM
Oct-02-23 08:00AM
Sep-25-23 01:33PM
Sep-20-23 12:13AM
Sep-19-23 09:00AM
Sep-13-23 08:30AM
Sep-05-23 12:31PM
08:00AM
Aug-28-23 12:00PM
Aug-12-23 08:04AM
Aug-09-23 08:40AM
Aug-08-23 08:00AM
Jul-31-23 01:39PM
(The Wall Street Journal)
Jul-27-23 04:05PM
TPG, Inc. operates as a global, diversified alternative asset management firm. It invests across five multi-product platforms: Capital, Growth, Impact, Real Estate, and Market Solutions. The firm aims to build dynamic products and options for its clients while also instituting discipline and operational excellence across the investment strategy and performance of its portfolio. The company was founded by Jim Coulter and David Bonderman in 1992 and is headquartered in Fort Worth, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MESSEMER DEBORAH M. Director Jul 17 '24 Sale 46.55 4,089 190,332 17,536 Jul 17 05:37 PM MESSEMER DEBORAH M. Director Feb 28 '24 Sale 43.97 6,390 280,980 18,033 Mar 01 05:14 PM Vazquez-Ubarri Anilu Chief Operating Officer Feb 27 '24 Option Exercise 0.00 101,937 0 435,648 Feb 29 07:23 PM Vazquez-Ubarri Anilu Chief Operating Officer Feb 29 '24 Sale 41.64 101,937 4,244,657 333,711 Feb 29 07:23 PM WINKELRIED JON Chief Executive Officer Feb 27 '24 Option Exercise 0.00 1,000,000 0 4,326,460 Feb 29 07:01 PM WINKELRIED JON Chief Executive Officer Feb 29 '24 Sale 41.64 1,000,000 41,640,000 3,326,460 Feb 29 07:01 PM WINKELRIED JON Chief Executive Officer Feb 29 '24 Sale 41.64 50,848 2,117,311 0 Feb 29 07:01 PM Weingart Jack Chief Financial Officer Feb 27 '24 Option Exercise 0.00 308,468 0 1,084,450 Feb 29 06:57 PM Weingart Jack Chief Financial Officer Feb 29 '24 Sale 41.64 308,468 12,844,608 775,982 Feb 29 06:57 PM Trujillo David Director Feb 27 '24 Option Exercise 0.00 397,510 0 580,029 Feb 29 06:45 PM Trujillo David Director Feb 29 '24 Sale 41.64 397,510 16,552,316 182,519 Feb 29 06:45 PM Sisitsky Todd Benjamin President Feb 27 '24 Option Exercise 0.00 660,151 0 1,172,917 Feb 29 06:43 PM Sisitsky Todd Benjamin President Feb 29 '24 Sale 41.64 660,151 27,488,688 512,766 Feb 29 06:43 PM Sisitsky Todd Benjamin President Feb 29 '24 Sale 41.64 52,807 2,198,883 396,982 Feb 29 06:43 PM Sarvananthan Ganendran Director Feb 27 '24 Option Exercise 0.00 162,707 0 215,093 Feb 29 06:41 PM Sarvananthan Ganendran Director Feb 29 '24 Sale 41.64 172,705 7,191,436 42,388 Feb 29 06:41 PM Rhodes Jeffrey K. Director Feb 27 '24 Option Exercise 0.00 408,675 0 585,167 Feb 29 06:38 PM Rhodes Jeffrey K. Director Feb 29 '24 Sale 41.64 408,675 17,017,227 176,492 Feb 29 06:38 PM Raj Nehal Director Feb 27 '24 Option Exercise 0.00 250,858 0 800,570 Feb 29 06:36 PM Raj Nehal Director Feb 29 '24 Sale 41.64 250,858 10,445,727 549,712 Feb 29 06:36 PM Harris Joann Chief Compliance Officer Feb 27 '24 Option Exercise 0.00 23,745 0 23,745 Feb 29 06:33 PM Harris Joann Chief Compliance Officer Feb 29 '24 Sale 41.64 23,745 988,742 0 Feb 29 06:33 PM Harris Joann Chief Compliance Officer Feb 29 '24 Sale 41.64 1,739 72,412 22,860 Feb 29 06:33 PM Davis Kelvin L. Director Feb 27 '24 Option Exercise 0.00 822,017 0 1,666,601 Feb 29 06:29 PM Davis Kelvin L. Director Feb 29 '24 Sale 41.64 822,017 34,228,788 844,584 Feb 29 06:29 PM Davidson Martin Chief Accounting Officer Feb 27 '24 Option Exercise 0.00 39,317 0 70,308 Feb 29 06:26 PM Davidson Martin Chief Accounting Officer Feb 29 '24 Sale 41.64 39,317 1,637,160 30,991 Feb 29 06:26 PM COULTER JAMES G Executive Chairman Feb 27 '24 Option Exercise 0.00 1,250,000 0 1,266,949 Feb 29 06:24 PM COULTER JAMES G Executive Chairman Feb 29 '24 Sale 41.64 1,334,746 55,578,823 0 Feb 29 06:24 PM COULTER JAMES G Executive Chairman Feb 29 '24 Sale 41.64 16,949 705,756 386,936 Feb 29 06:24 PM COSLET JONATHAN J Director Feb 27 '24 Option Exercise 0.00 1,000,000 0 1,000,000 Feb 29 06:22 PM COSLET JONATHAN J Director Feb 29 '24 Sale 41.64 1,000,000 41,640,000 0 Feb 29 06:22 PM Chorengel Maya Director Feb 27 '24 Option Exercise 0.00 69,298 0 131,919 Feb 29 06:20 PM Chorengel Maya Director Feb 29 '24 Sale 41.64 74,773 3,113,548 57,146 Feb 29 06:20 PM BONDERMAN DAVID Director Feb 27 '24 Option Exercise 0.00 1,500,000 0 1,516,949 Feb 29 06:18 PM BONDERMAN DAVID Director Feb 29 '24 Sale 41.64 1,584,746 65,988,823 0 Feb 29 06:18 PM BONDERMAN DAVID Director Feb 29 '24 Sale 41.64 16,949 705,756 37,967 Feb 29 06:18 PM Berenson Bradford General Counsel Feb 27 '24 Option Exercise 0.00 90,895 0 287,147 Feb 29 06:15 PM Berenson Bradford General Counsel Feb 29 '24 Sale 41.64 90,895 3,784,868 196,252 Feb 29 06:15 PM
Index RUT
P/E -
EPS (ttm) -1.61
Insider Own 33.98%
Shs Outstand 167.13M
Perf Week 0.59%
Market Cap 534.28M
Forward P/E -
EPS next Y -1.46
Insider Trans 2.44%
Shs Float 138.06M
Perf Month 0.99%
Income -278.45M
PEG -
EPS next Q -0.33
Inst Own 66.85%
Short Float 28.48%
Perf Quarter -0.58%
Sales 0.09M
P/S 5936.40
EPS this Y 33.75%
Inst Trans 28.36%
Short Ratio 20.93
Perf Half Y -13.97%
Book/sh 2.46
P/B 1.04
EPS next Y -5.43%
ROA -39.28%
Short Interest 39.32M
Perf Year -9.40%
Cash/sh 2.13
P/C 1.20
EPS next 5Y 1.00%
ROE -48.94%
52W Range 2.01 - 5.78
Perf YTD -20.40%
Dividend Est. -
P/FCF -
EPS past 5Y 22.18%
ROI -46.25%
52W High -55.76%
Beta 0.83
Dividend TTM -
Quick Ratio 12.25
Sales past 5Y -27.79%
Gross Margin -16467.44%
52W Low 27.11%
ATR (14) 0.20
Dividend Ex-Date -
Current Ratio 12.25
EPS Y/Y TTM 34.36%
Oper. Margin -314866.28%
RSI (14) 45.66
Volatility 10.48% 6.96%
Employees 233
Debt/Eq 0.18
Sales Y/Y TTM -24.70%
Profit Margin -323780.23%
Recom 1.53
Target Price 9.26
Option/Short Yes / Yes
LT Debt/Eq 0.17
EPS Q/Q 34.27%
Payout -
Rel Volume 1.18
Prev Close 2.64
Sales Surprise -99.92%
EPS Surprise 0.00%
Sales Q/Q -100.00%
Earnings Nov 07 AMC
Avg Volume 1.88M
Price 2.56
SMA20 -4.80%
SMA50 -5.02%
SMA200 -19.80%
Trades
Volume 2,208,002
Change -3.22%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-08-24 Resumed
Oppenheimer
Outperform
$13 → $11
May-31-24 Initiated
Piper Sandler
Overweight
$11
Jan-05-24 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Jan-05-24 Downgrade
Guggenheim
Buy → Neutral
Dec-08-23 Initiated
Citigroup
Buy
$7
Dec-08-23 Initiated
Citigroup
Buy
Jun-26-23 Resumed
Oppenheimer
Outperform
$28
Mar-21-23 Initiated
Bernstein
Mkt Perform
$6
Jan-24-23 Upgrade
JP Morgan
Neutral → Overweight
$20 → $11
Jan-06-23 Upgrade
Robert W. Baird
Neutral → Outperform
$12
Dec-12-22 Downgrade
BofA Securities
Buy → Underperform
$24 → $9
Aug-10-22 Downgrade
Raymond James
Outperform → Mkt Perform
Jul-15-22 Upgrade
Goldman
Neutral → Buy
$9 → $32
Jun-03-22 Initiated
Robert W. Baird
Neutral
$11
Feb-28-22 Reiterated
B. Riley Securities
Buy
$30 → $21
Oct-20-21 Initiated
Cowen
Outperform
Oct-08-21 Downgrade
Stifel
Buy → Hold
$44 → $18
Oct-08-21 Downgrade
Goldman
Buy → Neutral
$71 → $20
Sep-23-21 Upgrade
Raymond James
Mkt Perform → Outperform
Jun-21-21 Resumed
Jefferies
Buy
$53
Show Previous Ratings
Today 10:01AM
Oct-30-24 08:30AM
Oct-29-24 08:30AM
Oct-22-24 04:05PM
Oct-03-24 07:19AM
08:30AM
Loading…
Sep-30-24 08:30AM
Sep-26-24 08:30AM
Sep-14-24 05:39PM
Sep-06-24 11:31AM
Aug-08-24 09:50AM
08:30AM
06:00AM
Aug-07-24 04:10PM
(Associated Press Finance)
04:02PM
Jul-31-24 08:30AM
08:30AM
Loading…
Jul-01-24 08:30AM
Jun-27-24 10:13AM
Jun-26-24 04:36PM
Jun-20-24 08:30AM
Jun-12-24 11:30AM
May-29-24 08:55AM
May-28-24 04:05PM
May-23-24 08:30AM
May-21-24 01:56PM
Hedge Fund and Insider Trading News: Ken Griffin, Sanjay Shah, David Tepper, Stanley Druckenmiller, Michael Burry, Cevian Capital, Elliott Management, Millennium Management, Eisler Capital, Allogene Therapeutics Inc (ALLO), Carvana Co. (CVNA) and More
(Insider Monkey)
08:16AM
May-16-24 08:13AM
May-14-24 12:56PM
09:14AM
08:21AM
03:06AM
08:55PM
Loading…
May-13-24 08:55PM
05:36PM
05:10PM
04:47PM
04:17PM
(Associated Press Finance)
04:14PM
04:01PM
May-06-24 08:30AM
Apr-26-24 10:32AM
08:30AM
Apr-24-24 10:01AM
Apr-11-24 02:45PM
Apr-09-24 08:30AM
Apr-08-24 08:46AM
Mar-16-24 04:35PM
Mar-15-24 09:32AM
07:04AM
(Thomson Reuters StreetEvents)
Mar-14-24 08:55PM
05:34PM
05:15PM
04:15PM
(Associated Press Finance)
04:05PM
Mar-13-24 12:15PM
Mar-12-24 08:50AM
08:30AM
Mar-05-24 09:55AM
08:30AM
Feb-28-24 08:30AM
Feb-16-24 08:30AM
Jan-16-24 04:05PM
Jan-12-24 08:34AM
Jan-05-24 12:52PM
08:25AM
08:13AM
Jan-04-24 04:15PM
04:05PM
11:05AM
Jan-03-24 04:05PM
Dec-09-23 12:00PM
Dec-01-23 08:30AM
Nov-24-23 06:40AM
Nov-10-23 12:00PM
Nov-03-23 12:15PM
12:00PM
12:00PM
10:15AM
Nov-02-23 07:33PM
04:12PM
(Associated Press Finance)
04:02PM
09:00AM
Oct-30-23 08:30AM
Oct-26-23 08:30AM
Oct-16-23 09:26AM
08:30AM
Sep-27-23 09:09AM
Sep-25-23 08:45AM
Sep-05-23 08:30AM
Aug-29-23 07:30AM
Aug-23-23 12:26PM
Aug-17-23 08:44AM
Aug-14-23 08:30AM
Aug-03-23 11:20AM
Aug-02-23 05:25PM
04:13PM
04:02PM
10:41AM
Jul-26-23 08:30AM
Jun-15-23 09:30AM
Jun-14-23 08:00AM
Jun-09-23 06:25PM
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Parker Geoffrey M. Officer Oct 21 '24 Proposed Sale 2.84 36,404 103,501 Oct 21 04:05 PM Douglas Earl Martin Officer Aug 21 '24 Proposed Sale 2.79 28,310 78,844 Aug 21 04:18 PM MESSEMER DEBORAH M. Director Jun 18 '24 Sale 2.28 18,641 42,488 166,765 Jun 20 04:31 PM Humer Franz B Director May 30 '24 Sale 2.34 11,200 26,181 255,253 Jun 03 04:09 PM Belldegrun Arie Director May 16 '24 Buy 2.90 1,724,137 4,999,997 1,724,137 May 20 09:33 PM Parker Geoffrey M. CHIEF FINANCIAL OFFICER Jan 30 '24 Buy 3.60 190 683 819,590 Mar 06 09:52 PM MESSEMER DEBORAH M. Director Dec 18 '23 Sale 2.70 18,640 50,317 62,456 Dec 20 04:26 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite